Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1824 Target Snapshot

Receptor tyrosine-protein kinase erbB-2 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
6,230Compounds
1,093Assays
59Approved Drugs
6,835.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Receptor tyrosine-protein kinase erbB-2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 27 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P04626. Start with neoplasm, then reuse UniProt P04626 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P04626 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 27 linked drugs
Open source guide
Disease program
neoplasm

Receptor tyrosine-protein kinase erbB-2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 27 linked drugs remain visible in the same block.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AC-480, ANVATABART OPADOTIN, AV-412, BMS-690514. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 27 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Receptor tyrosine-protein kinase erbB-2 as ChEMBL target CHEMBL1824, mapped to UniProt P04626. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Receptor tyrosine-protein kinase erbB-2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1824
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P04626
Receptor tyrosine-protein kinase erbB-2
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Receptor tyrosine-protein kinase erbB-2 is the right protein anchor across sources, using UniProt P04626 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as approved-linked support. It currently carries 27 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameReceptor tyrosine-protein kinase erbB-2
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP04626
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelReceptor tyrosine-protein kinase erbB-2
UniProt AccessionP04626
Component TypeProtein
Sequence Length1255 aa

Receptor tyrosine-protein kinase erbB-2

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Receptor tyrosine-protein kinase erbB-2, mapped to UniProt P04626. Sequence length is 1255 aa.

Mapped IDP04626
Review nameReceptor tyrosine-protein kinase erbB-2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Receptor tyrosine-protein kinase erbB-2 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
neoplasm
27 linked drugs · 27 direct · 27 efficacy
Linked drugAC-480
Linked drugANVATABART OPADOTIN
Linked drugAV-412
Linked drugBMS-690514
Approved-linked Approved
breast cancer
24 linked drugs · 24 direct · 24 efficacy
Linked drugANVATABART OPADOTIN
Linked drugBMS-690514
Linked drugCP-724714
Linked drugCUDC-101
Approved-linked Approved
breast neoplasm
18 linked drugs · 18 direct · 18 efficacy
Linked drugANVATABART OPADOTIN
Linked drugCANERTINIB DIHYDROCHLORIDE
Linked drugCP-724714
Linked drugDISITAMAB VEDOTIN
Approved-linked Approved
cancer
17 linked drugs · 17 direct · 17 efficacy
Linked drugAC-480
Linked drugAEE-788
Linked drugANVATABART OPADOTIN
Linked drugBMS-690514
Approved-linked Approved
non-small cell lung carcinoma
15 linked drugs · 15 direct · 15 efficacy
Linked drugAFATINIB DIMALEATE
Linked drugBMS-690514
Linked drugCANERTINIB DIHYDROCHLORIDE
Linked drugCUDC-101
Approved-linked Approved
gastric cancer
13 linked drugs · 13 direct · 13 efficacy
Linked drugCUDC-101
Linked drugDISITAMAB VEDOTIN
Linked drugKN-026
Linked drugNERATINIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AC-480, ANVATABART OPADOTIN, AV-412, BMS-690514. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

59
Approved
15
Phase III
23
Phase II
6
Phase I
1
Phase 0.5
Assay Mix

Activity Type Distribution

IC505,169.0
KI1,437.0
EC5035.0
KD194.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5939267 10.22 IC50 0.06 Preclinical
CHEMBL941 10.22 IC50 0.06 Approved
CHEMBL6019933 10.05 IC50 0.09 Preclinical
CHEMBL5221067 9.85 IC50 0.14 Preclinical
CHEMBL5966664 9.85 IC50 0.14 Preclinical
CHEMBL5980010 9.82 IC50 0.15 Preclinical
CHEMBL5902815 9.82 IC50 0.15 Preclinical
CHEMBL6019427 9.8 IC50 0.16 Preclinical
CHEMBL5178703 9.8 IC50 0.16 Preclinical
CHEMBL6036674 9.74 IC50 0.18 Preclinical
Distribution

pChEMBL Value Distribution

262
5.0
277
5.5
469
6.0
443
6.5
609
7.0
563
7.5
383
8.0
138
8.5
45
9.0
13
9.5
pChEMBL
Approved Drugs

Approved Drugs

LAZERTINIB
CHEMBL4558324
Approved 2024
Properties Compare Identifier
TIRABRUTINIB
CHEMBL4071161
Approved 2020
Properties Compare Identifier
TUCATINIB
CHEMBL3989868
Approved 2020
Properties Compare Identifier
ZANUBRUTINIB
CHEMBL3936761
Approved 2019
Properties Compare Identifier
DACOMITINIB
CHEMBL2105719
Approved 2018
Properties Compare Identifier
DACOMITINIB ANHYDROUS
CHEMBL2110732
Approved 2018
Properties Compare Identifier
ACALABRUTINIB
CHEMBL3707348
Approved 2017
Properties Compare Identifier
BRIGATINIB
CHEMBL3545311
Approved 2017
Properties Compare Identifier
NERATINIB
CHEMBL180022
Approved 2017
Properties Compare Identifier
OSIMERTINIB
CHEMBL3353410
Approved 2015
Properties Compare Identifier
AFATINIB DIMALEATE
CHEMBL2105712
Approved 2013
Properties Compare Identifier
AFATINIB
CHEMBL1173655
Approved 2013
Properties Compare Identifier
IBRUTINIB
CHEMBL1873475
Approved 2013
Properties Compare Identifier
LAPATINIB DITOSYLATE
CHEMBL1201179
Approved 2007
Properties Compare Identifier
LAPATINIB
CHEMBL554
Approved 2007
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
SORAFENIB
CHEMBL1336
Approved 2005
Properties Compare Identifier
ERLOTINIB
CHEMBL553
Approved 2004
Properties Compare Identifier
GEFITINIB
CHEMBL939
Approved 2003
Properties Compare Identifier
IMATINIB
CHEMBL941
Approved 2001
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,093
Total Assays
2,525
Tested Compounds
3
Assay Types
Binding — 1,015 assays, 2,525 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 643 1,362 6.8
cell-based format 266 854 6.7
assay format 106 309 7.4
Functional — 72 assays, 263 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 55 81 6.5
assay format 15 182 6.5
organism-based format 2 0 —
ADME — 6 assays, 16 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 0 —
cell-based format 2 14 6.9
single protein format 2 2 7.0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine